Drugmakers turn to AI to speed trials, regulatory submissions

Artificial intelligence has yet to deliver on the most challenging aspect of drug development — finding new molecules that lead to major ‍medical advances — but it is already streamlining less glamorous parts of ​the process, industry executives say.

AI is helping find participants and sites for clinical trials and drafting documents for regulators, shaving weeks ⁠off these labor-intensive processes, seven large drugmakers and six smaller biotech companies said at the recent JP Morgan Healthcare Conference.